PREVENT-ADPKD is a multi-centre, open-label randomised controlled trial that tested the hypothesis that prescribed water intake to maintain hydration will reduce the progression of total kidney volume in participants with autosomal dominant polycystic kidney disease with eGFR> 30 ml/min/1.73 m2 and aged between 18-65 years old.
The trial commenced in December 2015 and recruited a total of 184 participants. Follow-up of study participants was for 3 years. The results were published in 2021 here: http://DOI: 10.1056/EVIDoa2100021
Participating sites included Sydney (Westmead Hospital, Nepean Hospital, Norwest Private Hospital, Liverpool Hospital, Prince of Wales Hospital and St George Hospital, and two private clinics), regional NSW (Wollongong Hospital, John Hunter Hospital, two private clinics in Gosford) and Perth (Sir Charles Gairdner Hospital).